Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hey buddy I'm here, patiently waiting in the wings. I liked the presentation as well. A little dry and clearly more scientific based than what most Wall st types want to hear, but the science seemed solid, they are really looking to hit a home run here, the level of microbiology and bone resorption analysis they have been willing to address, acknowledge, and pursue is unheard of. Feel they did well to avoid it being a purely PR/hype based conference. Those guys on the panel were legit, as boring as any I've ever listened to at high level conferences lol.
I think it would've been a large error to pay for the conference/PR without having prelim data analyses at least (which is fairly typical to have), I don't find it reasonable or believable to believe that mgmt has no concept of data, given the overall picture and timeline, and companies will usually acknowledge freely that their field researchers don't have data, as a component of running double blind, which is usually all they are required or willing to say. I also found it funny that they made no generalizations or vague links to pending data, ominously absent, and thankfully offered no hints about future directions or problem spots in the science, which seems very relevant on the brink of news. So I sit and wait lol. Hearing the sheer volume of studies and research they have accumulated in this field was eye opening. I was thoroughly impressed to see the level of knowledge they have in this area, and the working knowledge they have of FDA tracks and approvals avenues- a piece that is classically missing from discussions led by new companies... so it was surprising to see the level of thought they are using to approach. So I was a bit surprised and enthusiastic to hear their thoughts on potentials for our compound to (potentially) favorably impact bone remodeling and fracture healing, independent of the muscle growth. As an analogy, Instead of just throwing gasoline into an engine and boosting mood and offering short term gains that fade, they hint at the potential for our compound to change the mechanics of the car, to modify the rubber on the torn tires... this is a huge angle they are looking at as proof of concept... truly cannot be understated. If they are able to link the data and get in depth analyses of the long term bone effects, our drug could then be used off label in a number of pathological fracture scenarios with other fracture sites... making it an unlimited market. I still find it a stretch, and more of a dream, at this stage. That being said, if they can create a scenario where our drug shows independently favorable bone health and repair benefits, this has the potential to be a panacea for fracture care in elderly populations. Using it on people with less to lose (end of life, high mortality fractures) is a great place to get the data they would need, that would open this up to less terminal participants. It also makes their bone/muscle more generalized approach seemingly much better thought out than the niche indication that GTXI is exploring, that will likely restrict GTXI from entering our areas as competition, without a lot of additional trials on their end.
I have finalized my position for trial results, and hold about 3/4 of my original warrant position, along with about 1/4 of my common position. Very excited for the weeks ahead. If data looks good, I will probably abandon another 25% of my warrants, and close my common position. Wish I had the patience to hold it all through both trials, but for whatever reason my sleep is less restful with unspeakable sums of money tied into one stock ;)
Hope you're enjoying the ride buddy, the waiting game continues, take care
Good for almost another 10 years.
Not a vktx fundamental geek .. but, Isn't there patent issue longer term
Brother we are on the cusp of the VIKING GOLDEN CROSS!
http://stockcharts.com/h-sc/ui?s=VKTX
https://www.finviz.com/quote.ashx?t=vktx
YOu still with us brother? I thought the presentation was very nice. Meditating on it after the fact, I appreciate the no bs attitude of the speakers. Just frank, straight up and direct. HOping for a nice read out here.
Lets not forget the possibilities are endless here. Any ailment causing you to loose muscle could one day be complimented by VK5211. In the conference call they clearly mentioned that this could be a candidate for the more than 2mm knee replacements scheduled by 2018. I could also see this used for multiple broken bone situations where you are incapacitated for certain periods.
I think "The future is friendly" with this one.
Hard to know when data come in .. I am keeping through data as I believe even if so so , we start having a run up to $7 on vk2809
They have seen more data then you realize, Ligand has been working on this for years.
are you selling before results or holding ?
I'm holding for both vk5211 and vk2809 , if both get good data then
25.00 target Q1 JMHO
Per IR they are blinded .. so their confidence means little to me
Am still looks at $7 to $8 prior to readout
Read the Tea leaves ...it means they have CONFIDENCE to do a presentation for Wall st. Big Boys right before they release VK5211 results. The readout will come soon...stay long.
I listened .. means nothing to me until readout for p2 ..
Market absol on fire for spec biotechs .. vktx has got mdgl mojo
If you watched webcast did you like it ? anything new ? I was wondering about how Management would go about getting vk5211 approved for Knee replacement and leg fractures as well... would it be easy to do if Vk5211 gets FDA approved for the Hips ? it would not take another phase 3 trials would it ? what would be VKTX Management do to process in filing for other uses with FDA as they only have patent till 2025 -28 ? vk5211 could turn ou to be a Multi billion $$ drug
thanks Waffles, hope all is well.
Gotta be worth as much as it was at public offering!!
I like your style my friend!
Past is irrelevant ... but if you want to do the math, do it right .. you should look at market cap net of cash at IPO and now .. not stock price
Anyways, I am saying $9 now and not $5
can you elaborate a little sir? we should be valued at $5 right this moment. Underwriters took public at $10
Shld be $5 in vk2809 and $4 on vk5211 now .. $9 !!
No kidding !!
agreed, and the Chart setting up for a Golden cross as well.
http://stockcharts.com/h-sc/ui?s=VKTX
Stock will be over $10 if p2 meets primary .. in about 4 weeks
$2 to $3 is too low here for this potential reward ..
Mdgl is now valued above $15 a share in vktx terms
What a great day, congrats to the longs.
VKTX
So much more room to run, actually I think it might be good to let the stock run for a few more weeks before Phase 2 data results, that way we have a higher launch pad when results come getting the stock up into 7.00 -10.00 range. Would like to see it up around 4.00 before they release 5211 results. GLTA
VKTX
Listening to webcast now, its much more in depth and informative than the Renshaw Rodman presentation.
http://ir.vikingtherapeutics.com/webcasts-and-presentations?item=27
With only 35% public float, this could run nicely on positive data. GLTA!
Super undervalued here. Looking forward for to the market recognize this and adjust accordingly.
Very undervalued
But there goes your 90% news today !!
This should run up to at least $5 prior to read out ..
Sitting here watching my level 2 screen with a big smile.
VKTX
Thanks buddy, hope all is well
That is the key point here. The VKTX Market Cap is undervalued compared to other Biotechs that do not have as good of pipeline that VKTX has.
Warrants are 1.00 now . congrats my friend.
VKTX
Strong move up this morning, gaining Momentum $$$$$$$$$$$$
VKTX
Thor, God of VKTX Thunder !!!!!
WOw that is CLOSE!!!! The Norse Gods are on our side!!!
The Blessings of Valhalla will bring a Golden cross. Check out the Chart on the Verge.
http://stockcharts.com/h-sc/ui?s=VKTX
May the blessings of Valhalla be upon us this week.
Good point , The underwriters thought it was worth 10.00 a couple years ago. So with good Vk5211 results it should be 15.00 .
I believe when VKTX was taken public, the underwriter(s)were able to take it public at $10 per share. Nothing negative, that I can recall, has happened since it was valued at $10 per share....I believe its all been positive, albeit a little slower than anticipated.
I would be 100% happy with that.
Will go to $7 before readout on hip
If readout is good .. $15
If bad
$4 and then will move to $8 prior to VK2809 readout
Strange.. I have no missed calls
I was on a flight to Vegas yesterday evening maybe bad timing
Sounds good bud
I'll be at the rise festival so if I don't answer that's why
But I'm charging my phone now, should be good
No sir, still the same one. Ill message you in a little.
As in you called me? Did you change your numba
Hey bud looking good! Gave ya a holler yesterday.
Still .. vktx is a bargain !!
Rather than guessing I asked IR
Here is their answer
"The data is blinded. We have no access."
agreed, VKTX valuation is way to low compared to other Biotechs. 15.00 sounds reasonable.
Followers
|
110
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1995
|
Created
|
09/18/14
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |